Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer
暂无分享,去创建一个
L. Collette | C. Sternberg | J. Schornagel | A. V. van Oosterom | P. D. De Mulder | C. Théodore | M. Spina | C. V. van Groeningen | S. Fosså | P. Mulder | C. de Balincourt | C. V. Groeningen | A. Oosterom | F. Witjes | C. D. Balincourt | S. D. Fosså | S. Fosså
[1] P. Albers,et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] J. Baselga,et al. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] J. Eastham,et al. Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] H. Scher,et al. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract , 2000, Cancer.
[5] C. la Vecchia,et al. Urinary bladder cancer death rates in Europe. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] M. Mazumdar,et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] B. Redman,et al. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] R. Mick,et al. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] I. Tannock,et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] M. Mazumdar,et al. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] L. Einhorn,et al. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] C. Sternberg,et al. Escalated M-VAC chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients with advanced urothelial tract tumors. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] J. Gabrilove,et al. Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] I. Tannock,et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] N. Geller,et al. Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy , 1991, Cancer.
[16] C. Logothetis,et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] C. Logothetis,et al. Escalated therapy for refractory urothelial tumors: methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated recombinant human granulocyte-macrophage colony-stimulating factor. , 1990, Journal of the National Cancer Institute.
[18] N. Geller,et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse , 1989, Cancer.
[19] J. Gabrilove,et al. Effect of Granulocyte Colony-Stimulating Factor on Neutropenia and Associated Morbidity Due to Chemotherapy for Transitional-Cell Carcinoma of the Urothelium , 1989 .
[20] F. Freiha,et al. Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] N. Geller,et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. , 1985, The Journal of urology.
[22] C. Logothetis,et al. Combined intravenous and intra-arterial cyclophosphamide, doxorubicin, and cisplatin (CISCA) in the management of select patients with invasive urothelial tumors. , 1985, Cancer treatment reports.